Latest | Instant news on finance, ETFs, IPOs etc. _第21页 | NewTimeSpace

18:11

【JOINN (06127.HK): Subsidiaries Sign Three-Year Lease Agreements with Joinn Biologics Group, Transaction Fully Exempt as De Minimis Connected Transaction】NewTimeSpace News: On 28 August 2026, JOINN (06127.HK) announced that the Company and two of its subsidiaries had respectively entered into three-year lease agreements with the Joinn Biologics Group commencing 1 September 2026 for properties in Daxing District, Beijing; with the highest applicable percentage ratio below 0.1%, the transactions qualify as de minimis connected transactions under Rule 14A.76(1)(a) and are fully exempt from disclosure requirements.

Tag： JOINN 06127.HK Property lease

18:08

【QIAN XUN TECH (01640.HK): Disposes Entire Stake in Qian Xun HK for RMB 200,000, Constituting a Major Transaction】NewTimeSpace News: On 28 August 2026, QIAN XUN TECH (01640.HK) announced that it had entered into a sale agreement with Mr. Wu Dan to dispose of the entire issued share capital of Qian Xun HK for RMB 200,000; the disposal group has not actively operated since 2025 and the Company expects a slight loss of approximately RMB 400,000, with the disposal constituting a major transaction under Chapter 14 of the Listing Rules requiring shareholders' approval.

Tag： QIAN XUN TECH 01640.HK Disposal of Shares

18:03

【SINOTRANS (00598.HK): Enters Concert Party Agreement with Sinotrans Container Lines on Decisions of Antong Holdings】NewTimeSpace News: On 28 August 2026, SINOTRANS (00598.HK) announced that it had entered into a concert party agreement with Sinotrans Container Lines to act in concert on decisions of Antong Holdings; the Company and Sinotrans Container Lines hold approximately 3.98% and 14.94% of Antong Holdings respectively, and the arrangement constitutes a connected transaction with a percentage ratio above 0.1% but below 5%, exempt from independent shareholders' approval.

Tag： Sinotrans 00598.HK Concert Party Arrangement

18:02

【Going Global Weekly Report: Innovative Drugs Win Dense FDA Clearances; SHEIN and Mech-Mind Lead the Hong Kong Listing Wave - 20260828】This week's going-global focus centers on two threads: dense overseas clinical approvals for innovative drugs — two new drugs from CSPC PHARMA won US FDA recognition, and bispecific-antibody pipelines from BAO PHARMA and ANTENGENE received US and Australian regulatory approvals respectively — and accelerated Hong Kong financing, with SHEIN and Mech-Mind launching global offerings, LONGSYS passing its listing hearing, and LEADERDRIVE and Nazhen Technology advancing H-share listings. On the resources side, Mongolia's iron ore project has entered the construction phase and GUSHENGTANG is acquiring 100% of three Malaysian TCM institutions, as Chinese companies' global expansion evolves toward multidimensional coordination of technology, capital and channels.

Tag： Going Global Weekly Report GUSHENGTANG WAI CHUN BIOTEC YANCOAL AUS

17:58

【BAIYUNSHAN PH (00874.HK): Guangzhou Pharmaceutical Disposes Accounts Receivable of Approximately RMB 149 Million】NewTimeSpace News: On 28 August 2026, BAIYUNSHAN PH (00874.HK) announced that subsidiary Guangzhou Pharmaceutical had signed a delivery confirmation letter with Xingzheng Asset Management to sell accounts receivable with a book value of RMB 149 million, receiving a purchase price of RMB 146,322,872.24; aggregated with past transactions within 12 months, the percentage ratio exceeds 5% but is below 25%, constituting a discloseable transaction not requiring shareholder approval.

Tag： BAIYUNSHAN PH 00874.HK Disposal of Receivables

17:52

【HK Stock Connect Daily Report: SUNAC Jumps Over 10%, VGT Slips Nearly 13%, Expectations Grow for DIAGENS-B Inclusion in Stock Connect - 20260828】NewTimeSpace News: On 28 August 2026, the three major Hong Kong indices ended mixed, with the Hang Seng Index edging up 0.07% to 25,584.79 points, the Hang Seng TECH Index down 0.33%, and turnover at HKD 231.2 billion. Software stocks advanced, with KINGDEE INT'L up 6.23%; gold stocks led gains, with CHINAGOLDINTL up 7.72%; mainland property developers traded actively, with SUNAC up 10.66%. Storage and semiconductor technology names led declines, with VGT down 12.96%; large-model concepts were weak, with Z.AI down over 6% and MINIMAX down over 4%. Southbound capital recorded net buying of HKD 1.176 billion. TIANQI LITHIUM's interim net profit surged 4,925%, GUSHENGTANG's interim profit rose 45.5%, and DIAGENS-B has met the criteria for Stock Connect inclusion.

Tag： HK Stock Connect Daily Report HYGEIA HEALTH Tencent CIB CSI HK Equities Internet ETF Fullgoal CSI HK Equities Internet ETF

17:49

【BUSYMING (01768.HK): Plans Full Circulation of H Shares, Approximately 0.71% Domestic Shares Held by Director Wang Yutong to Be Converted into H Shares】NewTimeSpace News: On 28 August 2026, BUSYMING (01768.HK) issued an inside information announcement stating that it had applied to the CSRC to convert 1,536,088 domestic unlisted shares (par value RMB 1.00 each) held by director Mr. Wang Yutong, representing approximately 0.71% of the total issued share capital, into H shares for listing and trading on the Main Board, in a plan to implement the full circulation of H shares; the CSRC filing procedures have not yet been completed.

Tag： BUSYMING 01768.HK H-share full circulation

17:45

【CSPC PHARMA (01093.HK): Phase II Clinical Trial of SYH2069 Injection for Weight Management in Overweight or Obese Adults Launched at First Study Site in China】NewTimeSpace News: On 28 August 2026, CSPC PHARMA (01093.HK) announced that the Phase II clinical trial (SYH2069-004) of SYH2069 Injection for weight management in overweight or obese adult patients had been officially launched at the first study site in China; the product is a GLP-1R/GIPR dual-target dual-biased agonist that obtained the NMPA Drug Clinical Trial Approval Notice in December 2025.

Tag： CSPC PHARMA 01093.HK Clinical Trial

17:42

【SBP GROUP (01177.HK): LM-364 "Nectin-4ᵀᴹᴱ ADC" Obtains Clinical Trial Approvals from NMPA and FDA, Accelerating Global Clinical Development】NewTimeSpace News: On 28 August 2026, SBP GROUP (01177.HK) announced that LM-364 "Nectin-4ᵀᴹᴱ ADC", a national Class 1 innovative drug independently developed by wholly-owned subsidiary LaNova Medicines, had obtained implied clinical trial approval from China's NMPA for advanced solid tumors, after receiving FDA approval and initiating clinical trials in Australia in April this year; preclinical data disclosed at the 2026 AACR Annual Meeting showed TGI of up to 168.79% across PDX models.

Tag： SBP GROUP 01177.HK Clinical Trial

17:38

【HK.AI CAPITAL (01140.HK): Appoints Tsang Sze Wai as Executive Director, Former Templeton Executive and CEO of Multiple Nasdaq SPACs】NewTimeSpace News: On 28 August 2026, HK.AI CAPITAL (01140.HK) announced the appointment of Mr. Tsang Sze Wai as an executive director with effect from 28 August 2026, entitled to a director's fee of HKD 720,000 per annum; Mr. Tsang, aged 49, is a CFA charterholder and former Templeton Asset Management executive who has served as chief executive officer and chairman of multiple Nasdaq-listed SPACs.

Tag： HK.AI CAPITAL 01140.HK Appointment

17:33

【WEI YUAN HLDG (01343.HK): Accepts JTC Consent Letter for Redevelopment of New Headquarters in Singapore, Plot Ratio Raised to 1.40】NewTimeSpace News: On 28 August 2026, WEI YUAN HLDG (01343.HK) announced that WGC, its indirect wholly-owned subsidiary, has accepted the JTC consent letter to proceed with the redevelopment of the property in Singapore, raising the aggregate plot ratio from 0.85 and 0.90 to 1.40 on a combined basis, with completion required within two years from the date of the consent letter; the redevelopment may constitute a discloseable transaction under Chapter 14 of the Listing Rules.

Tag： WEI YUAN HLDG 01343.HK Redevelopment

17:26

【FRIENDTIMES (06820.HK): Controlling Shareholder Increases Stake by 1.6 Million Shares, Interest Rises to Approximately 57.51%】NewTimeSpace News: On 28 August 2026, FRIENDTIMES (06820.HK) announced that Warm Sunshine, held by controlling shareholder Mr. Jiang Xiaohuang, purchased 1,600,000 shares on the open market on 26 August 2026, representing approximately 0.07% of the total issued share capital; following the purchase, Mr. Jiang's interest increased to 1,254,108,157 shares, representing approximately 57.51% of the total issued share capital.

Tag： FRIENDTIMES 06820.HK Share Increase

17:25

【SIWI SCI & TECH (01202.HK): Terminates Possible Very Substantial Disposal of Subsidiary Interest via Public Listing】NewTimeSpace News: On 28 August 2026, SIWI SCI & TECH (01202.HK) announced the lapse and termination of the possible very substantial disposal of its entire interest in Putian New Materials via public listing, as no bids were received during the initial and extended listing periods, with no material adverse impact expected.

Tag： SIWI SCI & TECH 01202.HK Disposal Terminated

17:24

【CHK OIL (00632.HK): Jin Ailong Re-designated as CEO (China Business), Lam Pui Wang Appointed CEO (Global Business) and Huang Songjian Appointed Chief Risk Officer】NewTimeSpace News: On 31 August 2026, CHK OIL (00632.HK) announced that Mr. Jin Ailong has been re-designated from CEO to CEO (China Business), Mr. Lam Pui Wang has been appointed CEO (Global Business) and Mr. Huang Songjian has been appointed Chief Risk Officer, all effective from 31 August 2026 while continuing as executive directors; Mr. Jin receives HKD 1,320,000 per annum, while Mr. Lam and Mr. Huang each receive HKD 50,000 per month.

Tag： CHK OIL 00632.HK Board Change

17:22

【MOMENTUM FIN (01152.HK): Expects H1 Turnaround to Net Loss of Approximately HKD 3.2 Million】NewTimeSpace News: On 28 August 2026, MOMENTUM FIN (01152.HK) issued a profit warning, expecting an H1 consolidated net loss of approximately HKD 3.2 million, versus a net profit of approximately HKD 3.6 million a year earlier, driven by lower gross profit, higher expenses and higher income tax.

Tag： MOMENTUM FIN 01152.HK Profit Warning

17:22

【SHANDONG XINHUA (00719.HK): Dapoxetine Hydrochloride Tablets Obtain Drug Registration Certificate, Enriching Formulation Portfolio】NewTimeSpace News: On 28 August 2026, SHANDONG XINHUA (00719.HK) announced that its Dapoxetine Hydrochloride Tablets had obtained the Drug Registration Certificate from the National Medical Products Administration, with approval number Guoyao Zhunzi H20265706, at a specification of 30 mg under Chemical Drug Category 4, following an application filed and accepted in April 2025; dapoxetine sales in Chinese public medical institutions reached approximately RMB 1.03 billion in 2025, and the Company said the product would further enrich its formulation portfolio.

Tag： SHANDONG XINHUA 00719.HK drug registration application

16:44

【HK shares ETFs Daily Report: Fintech Leads Again! Taiwan and Gold Miners Advance in Tandem as Leveraged ChiNext and STAR 50 Retreat Under Pressure - 20260828】NewTimeSpace News: On 28 August 2026, fintech and Taiwan directions led the Hong Kong ETFs. The Global X Innovative Finance ETF (3185.HK) gained 2.39% and the Xtrackers MSCI Taiwan UCITS ETF (3036.HK) rose 2.11%; the Bosera Szse Chinext Daily (2x) Leveraged Product (7234.HK) fell 2.14%, with STAR 50 and China technology ETFs retreating broadly. NewTimeSpace monitoring showed a clear rotation featuring stronger regional defensive plays versus pressured China technology names.

Tag： HK Shares ETFs Daily Report Global X Innovative Finance ETF Bosera Szse Chinext Daily (2x) Leveraged Product

16:40

【NewTimeSpace | IPO Watch: Medcaptain, a Hidden Champion in Domestic Medical Devices, Seeks Hong Kong Listing, Leading Multiple Tracks in Life Support】NewTimeSpace News: Medcaptain Medical Technology Co., Ltd.(02041.HK) officially launched its H-share IPO on 28 August 2026. The offer price is set at HK$15.420 per share, with 100 shares per board lot and an entry cost of approximately HK$1,557.55. The company is expected to be listed on the Main Board of the Hong Kong Stock Exchange on 7 September 2026. A total of 38.9106 million shares will be offered globally, including 10% for Hong Kong public offer and 90% for international offer. The total fundraising amount is about HK$600 million, with net proceeds of roughly HK$496 million. The offer ratio stands at approximately 7.22%, and the total share capital after issuance will be around 539 million shares.

Tag： Medcaptain IPO 02041.HK IPO Watch Share Subscription

16:30

【Shanghai-Shenzhen Stock Connect ETFs Daily Report: Chemical ETFs Lead Against the Tide! Semiconductor Equipment Names Slump Over 3% Broadly as Sector Rotation Accelerates - 20260828】NewTimeSpace News: On 28 August 2026, chemical and petrochemical directions led the Shanghai-Shenzhen Stock Connect ETFs. The Tianhong CSI Subdivision Chemical Industry Theme ETF (159133.SZ) gained 2.33% and the E Fund CSI Petrochemical Industry ETF (516570.SH) rose 2.30%; the ChinaAMC China Science And Technology Innovation Board Semiconductor Material Equipment Theme ETF (588170.SH) fell 3.01%, with semiconductor equipment and STAR chip ETFs retreating broadly. NewTimeSpace monitoring showed a clear rotation featuring stronger chemicals and petrochemicals versus pressured semiconductor and chip names.

Tag： Shanghai-Shenzhen Stock Connect ETFs Daily Report Tianhong CSI Subdivision Chemical Industry Theme ETF ChinaAMC China Science And Technology Innovation Board Semiconductor Material Equipment Theme ETF

15:44

【Csop Samsung Electronics Daily (2x) Leveraged Product (07747.HK) Falls 6.38% in Afternoon Trade, AUM at HKD 8.211 Billion】NewTimeSpace News: As of August 28 at 15:47, Csop Samsung Electronics Daily (2x) Leveraged Product (07747.HK) fell 6.38%, with a latest price of HKD 72.480.

Tag： 07747.HK ETF Csop Samsung Electronics Daily (2x) Leveraged Product

Scan QR Code

Download App